TMEM37 and acute myeloid leukemia: Up to now, potential target antigens for AML treatment by CAR-T cells were under investigation, including CD33 [26], CD123 [22], CD38 [27], CD44v6 [28], FRβ [29], PR1/HLA-A2 [30], CLL-1 [31], and LeY [32].